Jill Marie Broadfoot - 04 Jun 2025 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
Director
Signature
/s/ Jill Marie Broadfoot by Colin Sandercock, attorney-in-fact
Issuer symbol
CUE
Transactions as of
04 Jun 2025
Net transactions value
$0
Form type
4
Filing time
06 Jun 2025, 16:00:05 UTC
Previous filing
04 Feb 2025
Next filing
24 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Broadfoot Jill Marie Director C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON /s/ Jill Marie Broadfoot by Colin Sandercock, attorney-in-fact 06 Jun 2025 0001305178

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Stock Option (right to buy) Award $0 +48,800 $0.000000 48,800 04 Jun 2025 Common Stock 48,800 $0.6200 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a stock option award granted pursuant to the Issuer's Director Compensation Policy.
F2 This option was granted on June 4, 2025. The shares underlying the option are scheduled to vest over three years with one-third vesting on the one-year anniversary of the grant date and the balance vesting in eight equal quarterly installments.